In this podcast, Paul Nioi, Vice President of Discovery and Translational Research at Alnylam Pharmaceuticals discusses the clinical development and manufacturing of RNA interference (RNAi) therapeutics. RNA interference (RNAi) medicines that can ‘silence’ or turn off the production of specific genes that cause or contribute to disease, are one of the exciting emerging modalities in drug development today. In this episode, EPR Editor Caroline Peachey catches up with Dr Paul Nioi, Vice President of Discovery and Translational Research at Alnylam Pharmaceuticals to explore clinical development and manufacturing of RNAi medicines for large patient populations.